Influence of tumour micro-environment heterogeneity on therapeutic response
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Influence of tumour micro-environment heterogeneity on therapeutic response
Authors
Keywords
-
Journal
NATURE
Volume 501, Issue 7467, Pages 346-354
Publisher
Springer Nature
Online
2013-09-17
DOI
10.1038/nature12626
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endothelial Cells Promote the Colorectal Cancer Stem Cell Phenotype through a Soluble Form of Jagged-1
- (2013) Jia Lu et al. CANCER CELL
- CSF1R Signaling Blockade Stanches Tumor-Infiltrating Myeloid Cells and Improves the Efficacy of Radiotherapy in Prostate Cancer
- (2013) J. Xu et al. CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells
- (2013) Urszula M. Polanska et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Markers of Response for the Antiangiogenic Agent Bevacizumab
- (2013) Diether Lambrechts et al. JOURNAL OF CLINICAL ONCOLOGY
- Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment
- (2013) V. T. Phan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma
- (2013) Krastan B. Blagoev et al. Cell Reports
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
- (2012) Kan V. Lu et al. CANCER CELL
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic Cancer
- (2012) Lauren J. Bayne et al. CANCER CELL
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic Neoplasia
- (2012) Yuliya Pylayeva-Gupta et al. CANCER CELL
- A Phase II, Randomized, Placebo-Controlled Study of Vismodegib as Maintenance Therapy in Patients with Ovarian Cancer in Second or Third Complete Remission
- (2012) S. B. Kaye et al. CLINICAL CANCER RESEARCH
- A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer
- (2012) J. Berlin et al. CLINICAL CANCER RESEARCH
- CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27- Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer
- (2012) J. S. Nielsen et al. CLINICAL CANCER RESEARCH
- Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
- (2012) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy
- (2012) Qin Mao et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
- (2012) Alicia S Chung et al. JOURNAL OF PATHOLOGY
- Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
- (2012) Mallika Singh et al. JOURNAL OF PATHOLOGY
- Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
- (2012) Jaafar Bennouna et al. LANCET ONCOLOGY
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- (2012) Ravid Straussman et al. NATURE
- Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
- (2012) Timothy R. Wilson et al. NATURE
- Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
- (2012) Mallika Singh et al. NATURE BIOTECHNOLOGY
- Reply to: Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
- (2012) Laurence Zitvogel et al. NATURE MEDICINE
- Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
- (2012) Metamia Ciampricotti et al. NATURE MEDICINE
- Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
- (2012) Yu Sun et al. NATURE MEDICINE
- Tumor-targeted TNF stabilizes tumor vessels and enhances active immunotherapy
- (2012) A. Johansson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases
- (2011) A M Jubb et al. BRITISH JOURNAL OF CANCER
- Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem Cell Niche and Promote Tumor Growth
- (2011) Michael Quante et al. CANCER CELL
- Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer
- (2011) Marie Tosolini et al. CANCER RESEARCH
- Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- (2011) Nikhil Wagle et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
- (2011) J. F. de Groot et al. NEURO-ONCOLOGY
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Functional Heterogeneity of Breast Fibroblasts Is Defined by a Prostaglandin Secretory Phenotype that Promotes Expansion of Cancer-Stem Like Cells
- (2011) Jenny A. Rudnick et al. PLoS One
- CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
- (2011) G. L. Beatty et al. SCIENCE
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
- (2011) David G. DeNardo et al. Cancer Discovery
- Endothelial Cell-Initiated Signaling Promotes the Survival and Self-Renewal of Cancer Stem Cells
- (2010) S. Krishnamurthy et al. CANCER RESEARCH
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- DNA Damage-Mediated Induction of a Chemoresistant Niche
- (2010) Luke A. Gilbert et al. CELL
- Macrophages, innate immunity and cancer: balance, tolerance, and diversity
- (2010) Alberto Mantovani et al. CURRENT OPINION IN IMMUNOLOGY
- Tumors as Organs: Complex Tissues that Interface with the Entire Organism
- (2010) Mikala Egeblad et al. DEVELOPMENTAL CELL
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- CD20+ B Cells: The Other Tumor-Infiltrating Lymphocytes
- (2010) B. H. Nelson JOURNAL OF IMMUNOLOGY
- B-cell-derived lymphotoxin promotes castration-resistant prostate cancer
- (2010) Massimo Ammirante et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- α-Smooth Muscle Actin Expressing Stroma Promotes an Aggressive Tumor Biology in Pancreatic Ductal Adenocarcinoma
- (2010) Hayato Fujita et al. PANCREAS
- Role of stromal myofibroblasts in invasive breast cancer: stromal expression of alpha-smooth muscle actin correlates with worse clinical outcome
- (2010) Masako Yamashita et al. Breast Cancer
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Paracrine Hedgehog Signaling in Cancer
- (2009) J.-W. Theunissen et al. CANCER RESEARCH
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models
- (2009) F. Shojaei et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer
- (2008) M. Schmidt et al. CANCER RESEARCH
- Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone Marrow
- (2008) Feng-Chun Yang et al. CELL
- Gene Expression Profile and Angiogenic Markers Correlate with Response to Neoadjuvant Bevacizumab Followed by Bevacizumab plus Chemotherapy in Breast Cancer
- (2008) S. X. Yang et al. CLINICAL CANCER RESEARCH
- Translational Research Working Group Developmental Pathway for Immune Response Modifiers
- (2008) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Vascular normalization in Rgs5-deficient tumours promotes immune destruction
- (2008) Juliana Hamzah et al. NATURE
- No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas
- (2008) Wen Qiu et al. NATURE GENETICS
- Stromal gene expression predicts clinical outcome in breast cancer
- (2008) Greg Finak et al. NATURE MEDICINE
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody
- (2008) R. Bargou et al. SCIENCE
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now